Hypothalamic energy homeostasis is orchestrated by two anatomically and functionally opposing neuronal populations in the arcuate nucleus (ARC): the orexigenic neuropeptide Y/agouti-related peptide (NPY/AgRP) neurons and the anorexigenic pro-opiomelanocortin/cocaine-and-amphetamine-regulated transcript (POMC/CART) neurons. These populations integrate peripheral hormonal signals—leptin, insulin, ghrelin, GLP-1—and project to downstream nuclei including the paraventricular nucleus (PVN), lateral hypothalamic area (LHA), and ventromedial hypothalamus (VMH). Peptides that modulate these circuits represent a primary research axis for understanding metabolic disease and satiety pharmacology.
NPY/AgRP Neurons: Orexigenic Signaling Architecture
NPY/AgRP co-expressing neurons in the ARC constitute the primary orexigenic drive. NPY acts via Y1R, Y2R, Y4R, and Y5R—all Gi-coupled GPCRs that reduce cAMP and inhibit adenylyl cyclase. Y1R and Y5R in the PVN mediate NPY's acute hyperphagia; Y2R acts as a presynaptic autoreceptor reducing NPY release. AgRP is an endogenous inverse agonist at MC3R and MC4R, reversing constitutive melanocortin tone and thereby disinhibiting feeding. A single genetic activation of AgRP neurons in mice produces hyperphagia within 20–30 minutes and sustained body weight gain over 72 hours—demonstrating the speed and potency of this orexigenic arm. Ghrelin, secreted from gastric X/A cells during fasting, activates GHS-R1a (growth hormone secretagogue receptor 1a) on AgRP neurons, potentiating NPY/AgRP release and increasing ARC neuronal firing rate approximately 30–50% in slice electrophysiology preparations.
POMC/CART Neurons: Anorexigenic Counter-Circuit
POMC-derived peptides include α-MSH (alpha-melanocyte-stimulating hormone), which acts as an endogenous agonist at MC3R and MC4R. MC4R is expressed densely in the PVN and is the primary mediator of melanocortin-induced anorexia; constitutive MC4R activation reduces food intake ~20–25% in rodents, while MC4R knockout mice develop severe obesity and hyperphagia. CART peptides (55–102 and 62–102) co-localize with POMC and augment anorexigenic signaling, though their cognate receptor remains officially uncharacterized. POMC/CART neurons receive leptin activation directly via LepRb → JAK2/STAT3 → POMC transcription, while AgRP neurons are inhibited by leptin, creating a dual regulatory mechanism for body weight set-point regulation. In leptin-deficient ob/ob mice, POMC expression in ARC is markedly reduced (~60% versus wild-type by in situ hybridization), with corresponding AgRP overexpression.
GLP-1R, MC4R, and GHS-R1a: Pharmacological Access Points
Three receptor systems are most actively interrogated in peptide-based appetite research. GLP-1R (glucagon-like peptide-1 receptor), a class B GPCR, is expressed on both peripheral vagal afferents and central ARC/PVN neurons. Centrally administered GLP-1 analogs reduce food intake through activation of cAMP/PKA and PI3K/Akt pathways, and increase POMC neuron firing. Retatrutide's triple agonism at GLP-1R, GIP-R (glucose-dependent insulinotropic polypeptide receptor), and glucagon receptor creates simultaneous peripheral satiety signaling and central hypothalamic suppression. In Phase II trials, retatrutide (12 mg/week) produced mean weight loss of ~17.5% at 24 weeks—among the largest reported for any pharmacological agent outside bariatric surgery. MC4R agonists, including the melanocortin PT-141 (bremelanotide), access hypothalamic circuits but their primary characterized site of action is in the medial preoptic area and limbic system for arousal, not primarily appetite. GHS-R1a inverse agonists remain under development as anti-ghrelin strategies to reduce AgRP neuron activation.
Peptide Research Targets and Preclinical Parameters
Modeling appetite circuitry in preclinical systems requires attention to species-specific ARC organization. Rats and mice differ substantially in leptin receptor distribution and NPY fiber density compared to primates. Key experimental approaches include: designer receptor exclusively activated by designer drugs (DREADDs) for NPY/POMC neuronal chemogenetics, Seahorse-based metabolic phenotyping in hypothalamic organoids, and in vivo fiber photometry for ARC population-level calcium imaging.
- NPY/Y1R antagonism: BIBP 3226, BMS193885; IC₅₀ ranges 1–50 nM depending on assay
- MC4R agonism: MT-II, bremelanotide; EC₅₀ at MC4R ~0.5–5 nM (competitive binding)
- GLP-1R agonism: GLP-1 (7-36) amide, semaglutide analogs; Ki ~0.3–1 nM
- GHS-R1a activation: Ipamorelin, hexarelin; EC₅₀ at GHS-R1a ~1–10 nM
- Purity standard: HPLC >99%, lot-traceable CoA for all hypothalamic circuit research reagents
All compounds referenced are for laboratory and research use only. They are not approved for therapeutic, diagnostic, or clinical use in humans, and investigators should observe applicable biosafety and ethical protocols in their jurisdictions.